{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-042341","form_type":"8-K","ticker":"FTRE","cik":"0001965040","company_name":"Fortrea Holdings Inc.","filed_at":"2025-09-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.715276+00:00","generated_at":"2026-05-17T06:01:23.460566+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Fortrea appoints William Sharbaugh as Class III director effective Sept 22, 2025","bullets":["William Sharbaugh appointed to Fortrea Board as Class III director, effective Sept 22, 2025.","Sharbaugh served as COO of PPD, Inc. from 2007-2021 and held roles at Bristol-Myers Squibb and Merck.","No committee assignments yet; will receive standard non-employee director compensation per existing policy.","Sharbaugh currently chairs Ora LLC and serves on boards of Launch Therapeutics, Alcami, and BioCare."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-042341","json":"https://secwatch.observer/filing/0001628280-25-042341.json","markdown":"https://secwatch.observer/filing/0001628280-25-042341.md","text":"https://secwatch.observer/filing/0001628280-25-042341.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1965040/000162828025042341/0001628280-25-042341-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1965040/000162828025042341/ftre-20250919.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:01:23.460566+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}